Merck Sharp & Dohme Biologics (Ireland) Ltd. is a subsidiary of Merck & Co. Inc., New Jersey, USA, one of the leading healthcare companies in the world. The company is investing €200 million in a new strategic vaccine facility in Carlow town.

The investment was announced by Minister for Enterprise, Trade and Employment Micheál Martin TD on Tuesday 27th November 2007. The project will support Merck’s expanding global business in human vaccines and biologics and will create 170 new high quality jobs by 2011. It will employ a highly skilled and technically sophisticated workforce across all areas of management, quality control, production, engineering, R&D and administration.

The new Carlow facility, which will be the first stand-alone human vaccine project in Ireland, will involve a formulation and sterile filling operation and an R&D team to support a number of recently launched vaccines and new products in the future.

“This investment is a further very strong commitment to Ireland by Merck which already has substantial and successful operations in Ireland. I was very pleased a year ago to announce that the company was investing in a new Formulation R&D and manufacturing facility at its manufacturing plant in South Tipperary and I'm delighted to see that construction on this project commenced last month. This latest investment represents a very significant consolidation of Ireland’s high profile position as a successful location for substantial biotechnology global investments,” added Minister Martin.

Vacancies
Find out about current vacancies at our Carlow plant.